Medical Affairs Manager

Key Responsibilities

• Support cross-functional launch readiness and critical business operations post-launche activities
• Develop and continuously maintain the highest scientific and medical expertise within TTR Cardiomyopathy (CM) and be acknowledged internally and externally as an expert in this area, developing peer-to-peer scientific relationships with HCPs and giving medical support to the corresponding cross-functional disease area teams.
• Collaborate with the Medical Affairs Manager for TTR Polyneuropathy to develop and implement a comprehensive Country Medical Affairs plan and strategy, to support disease awareness, best clinical practice and the overall corporate objectives.
• Identify key opinion leaders and cultivate a network of experts for TTR CM
• Initiate and support high impact medical education activities, including congress symposia, hospital/health care professional educational meetingsas well as provide medical and scientific input into the planning and execution of advisory boards.
• Actively engage with International& Global Medical Affairs and other functions, providing medical leadership within TTR CM to ensure the effective local implementation of Alnylam strategy and appropriate use of local market intelligence and development opportunities.
• Collaborate with patient advocacy groups.
• Manage requests for Alnylam product supply in off-label and compassionate use cases in accordance with local laws and Alnylam procedures.
• Coordinate the timely and appropriate response to Medical Information inquiries, utilizing  global  medical information resources and in line with local regulatory requirements.
• Support internal stakeholder for the Market Access process including AMNOG Training internal team members in relevant therapy areas and product training

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.